Heart · 2020 · 40 citations · 23 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical CardiologyPreventive CardiologyAortic DiseaseAortic StenosisAortic Valve DiseaseCardiac BiomarkersCardiovascular DiseaseCardiovascular MedicineAortic Valve Calcification ProgressionAortic Valve Disease PrognosisAortic Valve EvaluationAortic Valve HemodynamicsAortic Valve PathophysiologyAortic Valve SclerosisOxidized PhospholipidsProteomic Data Analysis
Objective This study assessed whether apolipoprotein CIII-lipoprotein(a) complexes (ApoCIII-Lp(a)) associate with progression of calcific aortic valve stenosis (AS). Methods Immunostaining for ApoC-III was performed in explanted aortic valve leaflets in 68 patients with leaflet pathological grades of 1–4. Assays measuring circulating levels of ApoCIII-Lp(a) complexes were measured in 218 patients with mild–moderate AS from the AS Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. The progression rate of AS, measured as annualised changes in peak aortic jet velocity (V peak ), and combined rates of aortic valve replacement (AVR) and cardiac death were determined. For further confirmation of the assay data, a proteomic analysis of purified Lp(a) was performed to confirm the presence of apoC-III on Lp(a). Results Immunohistochemically detected ApoC-III was prominent in all grades of leaflet lesion severity. Significant interactions were present between ApoCIII-Lp(a) and Lp(a), oxidised phospholipids on apolipoprotein B-100 (OxPL-apoB) or on apolipoprotein (a) (OxPL-apo(a)) with annualised V peak (all p<0.05). After multivariable adjustment, patients in the top tertile of both apoCIII-Lp(a) and Lp(a) had significantly higher annualised V peak (p<0.001) and risk of AVR/cardiac death (p=0.03). Similar results were noted with OxPL-apoB and OxPL-apo(a). There was no association between autotaxin (ATX) on ApoB and ATX on Lp(a) with faster progression of AS. Proteomic analysis of purified Lp(a) showed that apoC-III was prominently present on Lp(a). Conclusion ApoC-III is present on Lp(a) and in aortic valve leaflets. Elevated levels of ApoCIII-Lp(a) complexes in conjunction with Lp(a), OxPL-apoB or OxPL-apo(a) identify patients with pre-existing mild–moderate AS who display rapid progression of AS and higher rates of AVR/cardiac death. Trial registration NCT00800800 .
23
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Martin B. Leon, Craig R. Smith, Michael J. Mack et al. · New England Journal of Medicine · 2016 · 5K citations · Full text
Medicine, Cardiology, Surgery +13
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis
Kwan L. Chan, Koon Teo, Jean G. Dumesnil et al. · Circulation · 2010 · 795 citations